Showing 1241-1250 of 1477 results for "".
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- CureVac to Move COVID-19 Vaccine Into Late-Stage Testing on Positive Early Datahttps://modernod.com/news/curevac-to-move-covid-19-vaccine-into-late-stage-testing-on-positive-early-data/2478489/CureVac reported interim phase 1 study data on Monday showing that its experimental COVID-19 vaccine triggered strong binding and neutralizing antibody responses, and also gave a “first indication” that T-cells had been activated in a cohort of healthy adult volunteers. The company sa
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Fewer Side Effects Helped Spur Pfizer, BioNTech to Advance BNT162b2 Over Earlier COVID-19 Vaccine Candidatehttps://modernod.com/news/fewer-side-effects-helped-spur-pfizer-biontech-to-advance-bnt162b2-over-earlier-covid-19-vaccine-candidate/2478189/Pfizer and BioNTech released more details about why they recently selected their experimental coronavirus vaccine BNT162b2 over another candidate to advance into late-stage testing. According to a paper available on the medRxiv preprint server presenting additional phase 1 data from an ongoing US
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- Inovio Hints at Positive Early Phase 1 Safety Data for COVID-19 Vaccine INO-4800https://modernod.com/news/inovio-hints-at-positive-early-phase-1-safety-data-for-covid-19-vaccine-ino-4800/2477810/Inovio Pharmaceuticals suggested that preliminary safety data from an ongoing phase 1 trial indicates that its experimental COVID-19 DNA vaccine candidate INO-4800 appears to be safe in humans. “We are already seeing safety data and it has been benign,” commented R&D head K
- Early Data Show Moderna’s COVID-19 Vaccine Generates Immune Responseshttps://modernod.com/news/first-covid-19-vaccine-tested-in-the-us-shows-promise-in-data-from-eight-people/2477791/Moderna reported positive interim data from a phase 1 study of its vaccine candidate against SARS-CoV-2, with results showing that mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants in the low- and mid-dose cohorts, reaching or exceeding levels generally seen